Connection

Kit Simpson to HIV Infections

Back to Details
This is a "connection" page, showing publications Kit Simpson has written about HIV Infections.
Kit Simpson
Connection Strength
4.516
HIV Infections
  1. HIV economic burden of illness in the Veterans Health Administration population. AIDS Care. 2015; 27(1):123-31.
    View in: PubMed
    Score: 0.272
  2. Cost of treatment in a US commercially insured, HIV-1-infected population. PLoS One. 2014; 9(5):e98152.
    View in: PubMed
    Score: 0.266
  3. Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors. HIV Med. 2014 Sep; 15(8):488-98.
    View in: PubMed
    Score: 0.263
  4. Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden. AIDS Care. 2014 Apr; 26(4):466-75.
    View in: PubMed
    Score: 0.255
  5. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics. 2013 May; 31(5):427-44.
    View in: PubMed
    Score: 0.247
  6. Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies. Health Qual Life Outcomes. 2013 Mar 12; 11:42.
    View in: PubMed
    Score: 0.245
  7. The cost of Medicaid savings: the potential detrimental public health impact of neonatal circumcision defunding. Infect Dis Obstet Gynecol. 2012; 2012:540295.
    View in: PubMed
    Score: 0.238
  8. A cost-effectiveness analysis of anal cancer screening in HIV-positive women. J Low Genit Tract Dis. 2012 Jul; 16(3):275-80.
    View in: PubMed
    Score: 0.233
  9. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya. Value Health. 2011 Dec; 14(8):1048-54.
    View in: PubMed
    Score: 0.223
  10. Economic modeling of HIV treatments. Curr Opin HIV AIDS. 2010 May; 5(3):242-8.
    View in: PubMed
    Score: 0.201
  11. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther. 2009 Feb; 26(2):185-93.
    View in: PubMed
    Score: 0.185
  12. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009; 27(2):159-65.
    View in: PubMed
    Score: 0.183
  13. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials. 2008 Jul-Aug; 9(4):225-37.
    View in: PubMed
    Score: 0.177
  14. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Investig. 2007; 27(1):67-74.
    View in: PubMed
    Score: 0.159
  15. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Clin Drug Investig. 2007; 27(7):443-52.
    View in: PubMed
    Score: 0.159
  16. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig. 2007; 27(12):807-17.
    View in: PubMed
    Score: 0.159
  17. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004 Sep-Oct; 5(5):294-304.
    View in: PubMed
    Score: 0.136
  18. Impact of the COVID-19 Pandemic on the Care Continuum of Youth Living with HIV: Qualitative Study of the Scale It Up Program Clinical Sites. AIDS Behav. 2022 Dec; 26(12):4026-4033.
    View in: PubMed
    Score: 0.116
  19. Comparative Effectiveness of Community-Based vs Clinic-Based Healthy Choices Motivational Intervention to Improve Health Behaviors Among Youth Living With HIV: A Randomized Clinical Trial. JAMA Netw Open. 2020 08 03; 3(8):e2014650.
    View in: PubMed
    Score: 0.102
  20. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine. Value Health. 2000 May-Jun; 3(3):186-201.
    View in: PubMed
    Score: 0.100
  21. Improving the Youth HIV Prevention and Care Cascades: Innovative Designs in the Adolescent Trials Network for HIV/AIDS Interventions. AIDS Patient Care STDS. 2019 09; 33(9):388-398.
    View in: PubMed
    Score: 0.096
  22. Health economics in HIV disease. A review of the European literature. Pharmacoeconomics. 1999; 15 Suppl 1:1-12.
    View in: PubMed
    Score: 0.092
  23. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care. 1998 Jul; 4(7):1004-12.
    View in: PubMed
    Score: 0.088
  24. Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. AIDS Res Hum Retroviruses. 2014 Aug; 30(8):753-68.
    View in: PubMed
    Score: 0.067
  25. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-na?ve women of childbearing age. J Med Econ. 2014 Apr; 17(4):250-8.
    View in: PubMed
    Score: 0.065
  26. Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy. Adv Ther. 2010 Nov; 27(11):763-73.
    View in: PubMed
    Score: 0.052
  27. Piloting a method to measure satisfaction with HIV care. Am J Med Qual. 2010 Sep-Oct; 25(5):384-91.
    View in: PubMed
    Score: 0.051
  28. Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. J Acquir Immune Defic Syndr. 2000 Apr 01; 23(4):302-13.
    View in: PubMed
    Score: 0.025
  29. Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy. Obstet Gynecol. 1998 Feb; 91(2):174-81.
    View in: PubMed
    Score: 0.021
  30. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics. 1997 Jul; 12(1):54-66.
    View in: PubMed
    Score: 0.021
  31. The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios. Pharmacoeconomics. 2004; 22(18):1209-16.
    View in: PubMed
    Score: 0.008
  32. Measuring the effect of clinical guidelines on patient outcomes. Int J Technol Assess Health Care. 2000; 16(4):1013-23.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.